U.S., April 4 -- ClinicalTrials.gov registry received information related to the study (NCT06909474) titled 'Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies' on March 27.
Brief Summary: This is a clincal trial initiated by investigator to evaluate the safety and efficacy of anti-CD5 CAR-NK in the treatment of patients with relapsed/refractory T-Cell hematologic malignancies.
Study Start Date: March 27
Study Type: INTERVENTIONAL
Condition:
T-ALL/Lymphoma
Intervention:
BIOLOGICAL: Anti-CD5 CAR NK cells
Each patient will initially receive a single infusion of CAR-NK cells on Day 0. If a suboptimal response is observed after the first infusion (assessed by Day 28) and the safety profi...